submit url • add directory • physical therapy jobs
Related Topics:
Diagnostic RadiologyRadiology
Nuclear Pharmacy :: Pharmacy
Health Physics and Radiological Health :: Environmental Health
Today's News:
All Nuclear Medicine Jobs
Statewide :: Pennsylvania :: The Doctor Job
Looking for a job in a big city? Even if you've heard that a market is "saturated", wecan help! Many job openings for physicians may be hidden and unavailable unless you knowwhere to
Statewide :: Virginia :: The Doctor Job
Looking for a job in a big city? Even if you've heard that a market is "saturated", we can help! Many job openings for physicians may be hidden and unavailable unless you know where to look. An excellent
Statewide :: Texas :: The Doctor Job
Looking for a job in a big city? Even if you've heard that a market is "saturated", we can help! Many job openings for physicians may be hidden and unavailable unless you know where to look. An excellent
pubmed: 0161-5505
Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
Pfost B, Seidl C, Autenrieth M, Saur D, Bruchertseifer F, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R Related Articles Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice. J Nucl Med. 2009 Oct;50(10):1700-8 Authors: Pfost B, Seidl C, Autenrieth M, Saur D, Bruchertseifer F, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R Transurethral resection of urothelial carcinoma often results in tumor recurrence due to disseminated tumor cells. Therefore, new therapeutic strategies are urgently needed. The aim of this study was to establish an orthotopic human bladder carcinoma mouse model using the epidermal growth factor receptor (EGFR)-overexpressing bladder carcinoma cell line EJ28 and to compare therapeutic efficacy of intravesically instilled alpha-particle-emitting (213)Bi-anti-EGFR-monoclonal antibody (mAb) with mitomycin C. METHODS: Female Swiss nu/nu mice were intravesically inoculated with luciferase-transfected EJ28 human bladder carcinoma cells after the induction of urothelial lesions by electrocautery. At different time points after cell inoculation, mice were treated intravesically with (213)Bi-anti-EGFR-mAb, mitomycin C, or unlabeled anti-EGFR-mAb. Tumor development and therapeutic response were evaluated via bioluminescence imaging. RESULTS: Mice without therapy and those treated with unlabeled anti-EGFR-mAb reached a median survival of 41 d and 89 d, respectively. Mice that underwent therapy with 0.925 MBq of (213)Bi-anti-EGFR-mAb 1 h, 7 d, or 14 d after cell instillation survived more than 300 d in 90%, 80%, and 40% of the cases, respectively. Therapy with 0.37 MBq 1 h or 7 d after tumor cell inoculation resulted in survival of more than 300 d in 90% and 50% of mice, respectively. Mitomycin C treatment after 1 h and 7 d prolonged survival to more than 300 d in 40% and 50%, respectively; however, treatment turned out to be nephrotoxic. In contrast, no signs of nephrotoxicity could be observed after (213)Bi-anti-EGFR-mAb treatment. CONCLUSION: The study suggests that radioimmunotherapy using intravesically instilled (213)Bi-anti-EGFR-mAb is a promising option for treatment of bladder cancer in patients. PMID: 19793735 [PubMed - indexed for MEDLINE]
Weight-based, low-dose pediatric whole-body PET/CT protocols.
Alessio AM, Kinahan PE, Manchanda V, Ghioni V, Aldape L, Parisi MT Related Articles Weight-based, low-dose pediatric whole-body PET/CT protocols. J Nucl Med. 2009 Oct;50(10):1570-7 Authors: Alessio AM, Kinahan PE, Manchanda V, Ghioni V, Aldape L, Parisi MT Adult PET/CT acquisition protocols need to be modified for pediatric imaging to minimize the radiation dose while maintaining diagnostic utility. We developed pediatric PET/CT acquisition protocols customized to patient weight and estimated the dosimetry and cancer risk of these low-dose protocols to communicate basic imaging risks. METHODS: Protocols were developed for whole-body (18)F-FDG imaging of patients in PET mode with a weight-based injected activity (5.3 MBq/kg) and acquisition times (3-5 min/field of view) and for CT for attenuation correction and localization with a weight-based tube current ranging from 10 to 40 mAs. Patients were categorized on the basis of the Broselow-Luten color-coded weight scale. Dosimetry and radiation-induced cancer risk for the PET and CT acquisition in each category were derived from mean patient sizes and the interpolation of factors from accepted patient models. RESULTS: Whole-body pediatric PET/CT protocols require the customization of PET-acquisition settings and task-specific selection of CT technique. The proposed weight-based protocols result in an approximate effective dose ranging from 8.0 mSv for a 9-kg patient up to 13.5 mSv for a 63-kg patient. The radiation dose from the proposed protocols is 20%-50% (depending on patient weight), the dose from PET/CT protocols that use a fixed CT technique of 120 mAs and 120 kVp. The approximate, conservative estimate of additional lifetime attributable risk (LAR) of cancer incidence for females using the proposed protocols was approximately 3 in 1,000, with a variation of 18% across patient categories. For males, the additional LAR of cancer incidence was approximately 2 in 1,000, with a variation of 16% across categories. CONCLUSION: Low-dose PET/CT protocols for 11 patient weight categories were developed. The proposed protocols offer an initial set of acquisition parameters for pediatric PET/CT. The use of multiple categories allows for the continued refinement of dose-reduction parameters to minimize dose while maintaining image quality across the range of pediatric patient sizes. PMID: 19793734 [PubMed - indexed for MEDLINE]
MICoE areas of focus for 2010.
VanBrocklin HF Related Articles MICoE areas of focus for 2010. J Nucl Med. 2009 Oct;50(10):15N Authors: VanBrocklin HF PMID: 19793733 [PubMed - indexed for MEDLINE]
pubmed: 1532-6551
Shaping change, advancing quality...one patient at a time.
Related Articles Shaping change, advancing quality...one patient at a time. J Nucl Cardiol. 2009 Nov 5; Authors: PMID: 19890686 [PubMed - as supplied by publisher]
Subscribe to Nuclear_Medicine RSS feed 
Statewide :: Pennsylvania :: The Doctor Job
Looking for a job in a big city? Even if you've heard that a market is "saturated", wecan help! Many job openings for physicians may be hidden and unavailable unless you knowwhere to
Statewide :: Virginia :: The Doctor Job
Looking for a job in a big city? Even if you've heard that a market is "saturated", we can help! Many job openings for physicians may be hidden and unavailable unless you know where to look. An excellent
Statewide :: Texas :: The Doctor Job
Looking for a job in a big city? Even if you've heard that a market is "saturated", we can help! Many job openings for physicians may be hidden and unavailable unless you know where to look. An excellent
pubmed: 0161-5505
Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
Pfost B, Seidl C, Autenrieth M, Saur D, Bruchertseifer F, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R Related Articles Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice. J Nucl Med. 2009 Oct;50(10):1700-8 Authors: Pfost B, Seidl C, Autenrieth M, Saur D, Bruchertseifer F, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R Transurethral resection of urothelial carcinoma often results in tumor recurrence due to disseminated tumor cells. Therefore, new therapeutic strategies are urgently needed. The aim of this study was to establish an orthotopic human bladder carcinoma mouse model using the epidermal growth factor receptor (EGFR)-overexpressing bladder carcinoma cell line EJ28 and to compare therapeutic efficacy of intravesically instilled alpha-particle-emitting (213)Bi-anti-EGFR-monoclonal antibody (mAb) with mitomycin C. METHODS: Female Swiss nu/nu mice were intravesically inoculated with luciferase-transfected EJ28 human bladder carcinoma cells after the induction of urothelial lesions by electrocautery. At different time points after cell inoculation, mice were treated intravesically with (213)Bi-anti-EGFR-mAb, mitomycin C, or unlabeled anti-EGFR-mAb. Tumor development and therapeutic response were evaluated via bioluminescence imaging. RESULTS: Mice without therapy and those treated with unlabeled anti-EGFR-mAb reached a median survival of 41 d and 89 d, respectively. Mice that underwent therapy with 0.925 MBq of (213)Bi-anti-EGFR-mAb 1 h, 7 d, or 14 d after cell instillation survived more than 300 d in 90%, 80%, and 40% of the cases, respectively. Therapy with 0.37 MBq 1 h or 7 d after tumor cell inoculation resulted in survival of more than 300 d in 90% and 50% of mice, respectively. Mitomycin C treatment after 1 h and 7 d prolonged survival to more than 300 d in 40% and 50%, respectively; however, treatment turned out to be nephrotoxic. In contrast, no signs of nephrotoxicity could be observed after (213)Bi-anti-EGFR-mAb treatment. CONCLUSION: The study suggests that radioimmunotherapy using intravesically instilled (213)Bi-anti-EGFR-mAb is a promising option for treatment of bladder cancer in patients. PMID: 19793735 [PubMed - indexed for MEDLINE]
Weight-based, low-dose pediatric whole-body PET/CT protocols.
Alessio AM, Kinahan PE, Manchanda V, Ghioni V, Aldape L, Parisi MT Related Articles Weight-based, low-dose pediatric whole-body PET/CT protocols. J Nucl Med. 2009 Oct;50(10):1570-7 Authors: Alessio AM, Kinahan PE, Manchanda V, Ghioni V, Aldape L, Parisi MT Adult PET/CT acquisition protocols need to be modified for pediatric imaging to minimize the radiation dose while maintaining diagnostic utility. We developed pediatric PET/CT acquisition protocols customized to patient weight and estimated the dosimetry and cancer risk of these low-dose protocols to communicate basic imaging risks. METHODS: Protocols were developed for whole-body (18)F-FDG imaging of patients in PET mode with a weight-based injected activity (5.3 MBq/kg) and acquisition times (3-5 min/field of view) and for CT for attenuation correction and localization with a weight-based tube current ranging from 10 to 40 mAs. Patients were categorized on the basis of the Broselow-Luten color-coded weight scale. Dosimetry and radiation-induced cancer risk for the PET and CT acquisition in each category were derived from mean patient sizes and the interpolation of factors from accepted patient models. RESULTS: Whole-body pediatric PET/CT protocols require the customization of PET-acquisition settings and task-specific selection of CT technique. The proposed weight-based protocols result in an approximate effective dose ranging from 8.0 mSv for a 9-kg patient up to 13.5 mSv for a 63-kg patient. The radiation dose from the proposed protocols is 20%-50% (depending on patient weight), the dose from PET/CT protocols that use a fixed CT technique of 120 mAs and 120 kVp. The approximate, conservative estimate of additional lifetime attributable risk (LAR) of cancer incidence for females using the proposed protocols was approximately 3 in 1,000, with a variation of 18% across patient categories. For males, the additional LAR of cancer incidence was approximately 2 in 1,000, with a variation of 16% across categories. CONCLUSION: Low-dose PET/CT protocols for 11 patient weight categories were developed. The proposed protocols offer an initial set of acquisition parameters for pediatric PET/CT. The use of multiple categories allows for the continued refinement of dose-reduction parameters to minimize dose while maintaining image quality across the range of pediatric patient sizes. PMID: 19793734 [PubMed - indexed for MEDLINE]
MICoE areas of focus for 2010.
VanBrocklin HF Related Articles MICoE areas of focus for 2010. J Nucl Med. 2009 Oct;50(10):15N Authors: VanBrocklin HF PMID: 19793733 [PubMed - indexed for MEDLINE]
pubmed: 1532-6551
Shaping change, advancing quality...one patient at a time.
Related Articles Shaping change, advancing quality...one patient at a time. J Nucl Cardiol. 2009 Nov 5; Authors: PMID: 19890686 [PubMed - as supplied by publisher]
Sites:
American Board of Nuclear Medicine: The Board advances the health of the public through the establishment and maintenance of standards of training, and education, and the qualification of physicians rendering nuclear medicine services to the people of the United States.American College of Nuclear Physicians: A trade association that represents the interests of nuclear medicine physicians before legislative and regulatory bodies, other medical organizations, the media and general public.
American Society of Nuclear Cardiology: The American Society of Nuclear Cardiology is a professional medical society whose mission is to foster optimal delivery of nuclear cardiology services through professional education and training, the development of clinical guidelines, and the promotion of research.
Australian and New Zealand Society of Nuclear Medicine: About their history, branches, as well as their meetings and publications. Membership forms online.
British Nuclear Medicine Society: The British Nuclear Medicine Society web site gives information on medical events, adverse drug reactions and all other relevant information on nuclear medicine
Clinical Nuclear Medicine: Published monthly, with free abstracts, archived articles, and supscription details.
CNMT: Specializes in finding nuclear medicine jobs for nuclear medicine technologists.
CNR Nuclear Medicine Center: Research institute of the Italian National Research Council, focusing on diagnostic imaging of the central nervous system.
DrSpectScan.com: brain spect scanning and analysis, including before,and after any type of therapy for brain dysfunction. (analyses will be extended to the developing contributionsthat will come via PET and fMRI scanning), all modalities of bra...
European Association of Nuclear Medicine: European Association of Nuclear Medicine, Hollandstrasse 14 / Mezzanine, A-1020 Vienna, Austria Phone, +43 -1 - 2 12 80 30, Fax +43 -1 - 2 12 80 309
Hellenic Society of Nuclear Medicine: Based in Thessaloniki, Greece. Includes the Hellenic Journal of Nuclear Medicine.
History of Positron Imaging: A HISTORY OF POSITRON IMAGING
How Stuff Works: Nuclear Medicine: Nuclear materials get used in many forms of nuclear medicine -- everything from PET scans to chemotherapy uses them! Learn how nuclear medicine works!
Imaginis - Nuclear medicine imaging: Award-winning, breast cancer information and news resource. Imaginis also covers related breast cancer health topics such as hormone replacement therapy (HRT), heart disease, multiple sclerosis, osteoporosis, cervical cancer, and ovarian cancer, as well as, extensive information about medical pr...
Joint Program in Nuclear Medicine: Information on this program from Harvard Medical School.
Nuclear Imaging Westmead: Nuclear Imaging Westmead provides a full range of Nuclear imaging services including traditional radiology and advanced imaging to the health care sector.
Nuclear Medicine Communications: Monthly journal of the BNMS publishing research and clinical work in all areas of nuclear medicine. Submission guidelines and subscription details available.
Nuclear Medicine Information: This site provides information and breaking news about nuclear medicine, PET and related technologies.
Nuclear Medicine jobs: Nuclear Medicine jobs are listed at Physician Employment. You may register to be automatically updated when new jobs are listed.
Nuclear Medicine on the Net: This site features case studies and interactive case forums amongst other physician information resources, and gives a brief history of the topic for the layperson. [Uses Frames]
Nuclear Medicine Research Council: Provides a topical introduction, as well as its use in treating disease and the production and use of radioisotopes.
Nuclear Medicine Technology Resource: Nuclear Medicine Technology Resource WebSite
Positron Emission Tomography: Current and accurate information for patients about Nuclear Medicine, PET. Learn what you might experience, how to prepare for the exam, benefits, risks and more.
Positron Emission Tomography in oncology: Information is provided about the use of dynamic PET, including compartment modeling and parametric imaging, for cancer therapy management.
Radiation Emergency Assistance Center/Training Site: REAC/TS is available 24/7 to provide emergency medical services or advice/consultation related to incidents involving radiological or nuclear materials.
RadiologyInfo: Nuclear Medicine procedure menu
Society of Nuclear Medicine: An international scientific and professional organization founded in 1954 to promote the science, technology and practical application of nuclear medicine.
University of Kansas - Nuclear Medicine: Details about their program and equipment, radiopharamaceutics, quality control, radioimmunoassay and PET. Large collection of clinical and research teaching files.
This directory is based on the Open Directory and may have been modified
